|The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: Wiki
|PLACEBO GROUP Wiki
|BCG GROUP Wiki
|Mucocutaneous Lymph Node Syndrome NIH
|Bronchopulmonary Dysplasia NIH
|Urinary Tract Infections NIH
|Down Syndrome NIH
|Adrenal Insufficiency NIH
|Attention Deficit Disorder with Hyperactivity NIH
|Hemostatic Disorders NIH
|Blood Coagulation Disorders NIH
|Communicable Diseases NIH
|Severe Acute Respiratory Syndrome NIH
|Coronavirus Infections NIH
There is one clinical trial.
The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports